Biphasic changes in CB1Rs at early versus later stages of disease progression, in combination with brain structure-specific changes in CB1R expression, suggests a far more complex association of the endocannabinoid system with the progression of PD [368,374]. Here, CNR1 is linked to Parkinson disease.